Pembrolizumab Versus Placebo as second-line therapy in patients From Asia with advanced hepatocellular carcinoma: A randomized, double-blind, phase III trial
We evaluated the efficacy and safety of pembrolizumab in patients from Asia with previously treated advanced hepatocellular carcinoma (HCC).METHODSIn a double-blind, phase III trial, 453 patients with advanced HCC and progression during or after treatment with or intolerance to sorafenib or oxalipla...
Saved in:
Main Authors: | Qin, Shukui, Chen, Zhendong, Fang, Weijia, Ren, Zhenggang, Xu, Ruocai, Ryoo, Baek-Yeol, Meng, Zhiqiang, Bai, Yuxian, Chen, Xiaoming, Liu, Xiufeng, Xiao, Juxiang, Ho, Gwo Fuang, Mao, Yimin, Wang, Xin, Ying, Jieer, Li, Jianfeng, Zhong, Wenyan, Zhou, Yu, Siegel, Abby B., Hao, Chunyi |
---|---|
Format: | Article |
Published: |
American Society of Clinical Oncology
2023
|
Subjects: | |
Online Access: | http://eprints.um.edu.my/38540/ |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A promising response of refractory uterine leiomyosarcoma to pembrolizumab and temozolomide combination therapy
by: Lin, Rebecca, et al.
Published: (2024) -
Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE-063): A randomized, open-label, phase 3 trial in Asian patients
by: Chung, Hyun Cheol, et al.
Published: (2022) -
Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048
by: Rischin, Danny, et al.
Published: (2022) -
Critical requirements of integrated quality management system for project manager in construction
by: Sun, Zhendong
Published: (2015) -
An investigation of learner autonomy among EFL students in mainland Chinese universities
by: Cheng, Jianfeng
Published: (2019)